Journal List > Yonsei Med J > v.48(2) > 1030137

TOOLS
Cha, Park, Chung, Choi, Kim, and Park: Polymorphisms of CYP1A1 and GSTM1 Genes and Susceptibility to Oral Cancer
Original Article
Yonsei Medical Journal

Yonsei Medical Journal 2007; 48(2): 233-239.

Published online: 30 April 2007

DOI: https://doi.org/10.3349/ymj.2007.48.2.233

Polymorphisms of CYP1A1 and GSTM1 Genes and Susceptibility to Oral Cancer

In-Ho Cha1, 2, 3, Jong Yun Park4, Won-Yoon Chung2, 3, 5, Min-Ah Choi5, Hyung-Jun Kim1, 2, 3, Kwang-Kyun Park2, 3, 5

1Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, Seoul, Korea.

2Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul, Korea.

3Oral Science Research Institute, Yonsei University College of Dentistry, Seoul, Korea.

4Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL 33647, USA.

5Department of Oral Biology, Yonsei University College of Dentistry, Seoul, Korea.

Reprint address: requests to Dr. Kwang-Kyun Park, Department of Oral Biology, Yonsei University College of Dentistry, 134 Sinchon-dong, Seodaemoon-gu, Seoul 120-752, Korea. Tel: 82-2-2228-3056, Fax: 82-2-364-7113, biochelab@yumc.yonsei.ac.kr

Received 29 June 2006       Accepted 5 September 2006

Copyright © 2007 The Yonsei University College of Medicine

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

Oral cancer is the fifth most common form of cancer in the world and comprises 6.5% of all cancer deaths. Since one of the major risk factors for oral cancer is tobacco use, we hypothesized that polymorphic genes coding for tobacco carcinogen-metabolizing enzymes may play a role in oral cancer susceptibility.

Materials and Methods

To investigate the association between polymorphisms of the CYP1A1 and GSTM1 genes and risks for oral squamous cell carcinoma (OSCC) in the Korean population, the prevalence of the CYP1A1 Mspl and GSTM1 null polymorphisms were examined in 72 patients with histologically confirmed primary OSCC, as well as in 221 healthy control subjects.

Results

A significant risk increase for oral cancer was observed among subjects with the homozygous CYP1A1 (m2/m2) genotype (OR = 3.8, 95% CI = 1.9-7.7), but not the GSTM1 null genotype (OR = 0.7, 95% CI = 0.4-1.3). Risk for oral cancer was significantly increased in subjects with the homozygous CYP1A1 (m2/m2) genotype, regardless of smoking history (smokers; OR = 4.4; 95% CI = 1.2-16.3; non-smokers OR = 4.9; 95% CI=1.9-12.5). Using the potentially most protective genotype GSTM1 (+)/CYP1A1 [(m1/m1)+(m1/m2)] as the reference group, an increased risk for oral cancer was observed among subjects with the GSTM1 (+)/ CYP1A1 (m2/m2) (OR = 2.0, 95% CI = 0.8-5.2), and GSTM1 (-)/ CYP1A1 (m2/m2) (OR=4.9, 95% CI = 1.5-15.5) genotypes (p < 0.009, (χ2 trend test).

Conclusion

Our results suggest that individuals with a genotype of CYP1A1 (m2/m2) and GSTM1 (-) are highly susceptible for OSCC and that the CYP1A1 (m2/m2) genotype is closely associated with increased risk of OSCC in Koreans.

Keywords: Tobacco carcinogen-metabolizing enzyme, CYP1A1, GSTM1, genetic polymorphism, oral squamous cell carcinoma

INTRODUCTION

Oral cancer is a tobacco-related disease whose high incidence represents a significant problem in many parts of the world, with its poor survival rates, and severe functional and cosmetic defects accompanying its treatment. Most tobacco carcinogens require metabolic activation by cytochrome P450s (CYPs) for conversion into their reactive electrophilic intermediates1 and detoxification by glutathione S-transferases (GSTs) to produce water-soluble, excretable compounds.2 Variations in metabolism of these compounds are often associated with genetic polymorphisms in genes coding for enzymes involved in the metabolic activation or detoxification of tobacco carcinogens. Large differences in the prevalence of certain genetic polymorphisms have been described between ethnic and racial groups for several metabolizing enzyme genes, and it has been suggested that some of these polymorphisms may affect enzyme activity, which in turn may influence individual cancer risk.2-7
Tobacco carcinogens such as polycyclic aromatic hydrocarbons and tobacco-specific nitrosamines are primarily metabolized to their activated intermediates by the cytochrome P450-dependent mono-oxygenases. Several polymorphic cytochrome P450 enzymes involved in the activation of tobacco carcinogens have been examined for their potential association with increased risk for oral cancer.8-11 The CYP1A1 gene codes for the enzyme aryl hydrocarbon hydroxylase, which is involved in the biotransformation of various aromatic procarcinogens in cigarette smoke, including benzo[a]pyrene (BaP), to highly electrophilic and carcinogenic phenolic products and epoxides.1,12 Certain variant genotypes of CYP1A1 gene which cause enhanced enzymatic activity appear to play a role in susceptibility to adduct formation and, presumably, cancer risk. The CYP1A1 alleles containing the MspI polymorphic variants have been linked to increased formation of BaP-7,8-diol-epoxide adducts in white blood cells from coke oven workers.13 The CYP1A1 MspI polymorphism, which results from a single base pair change at nucleotide position 264 from the poly (A) signal in the 3' untranslated region of the CYP1A1 gene, is found in 5-30% of the population6,7,14-17 and has been linked to susceptibility for smoking-related cancers, such as oral and lung cancers.14,18,19
The mu class of GST enzymes plays an important role in the detoxification of BaP and other polycyclic aromatic hydrocarbons. The absence of GSTM1 enzyme activity for the detoxification (phase II) reaction is caused by homozygous deletion (null genotypes) of the respective genes20 and results in the accumulation of activated carcinogens that can bind covalently to DNA. The polymorphic GSTM1 null genotype has been found in 20-50% of populations of various ethnic origins, and this genotype has been correlated with risk for various tobacco-related cancers among Caucasians,4,21-23 Japanese10,11,24 and Indians.25 Significant associations were also found between the GSTM1 null genotype and the risk for oral squamous cell carcinoma (OSCC) in several studies.10,26 However, a lack of association between the GSTM1 polymorphism and oral cancer in Caucasians has been reported.8,27 These conflicting results may be due to ethnic differences in the allelic frequency of the GSTM1 polymorphism.
The present case-control study was done to investigate the potential role of CYP1A1 and GSTM1 gene polymorphisms in the risk for OSCC in Koreans.

MATERIALS AND METHODS

Study populations and sample processing

All cases (n = 72) comprised patients who had been histopathologically diagnosed for OSCC in the Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry (Seoul, Korea) between 1998 and 2000. Controls (n = 221) without any precancerous or cancerous lesions were recruited at a public school or College of Dentistry during routine dental screening. For all subjects, oral rinse samples were used for controls (n = 171) and oral biopsy samples collected during routine preventive dental screening or post treatment at dental clinics from the cases (n = 72) and a portion of the controls (n = 50) were used for the analysis of polymorphic genotypes. Buccal cells were collected from the 171 healthy controls by the mouthwash method as follows:28 1hr after brushing their teeth, the control subjects rinsed their mouths vigorously for 1 min with 10mL of undiluted mouthwash (Listerine, Warner-Lambert Consumer Healthcare, NJ, USA) and expelled it into a strerile 50-mL tube. The collected mouthwash was centrifuged at 2,700 rpm for 15 min, the supernatant discarded, and the pellet washed with 25mL of TE buffer (10mM Tris, pH 8.0, 10 mM EDTA, pH 8.0). The suspension was centrifuged again and the pellet used for DNA extraction.
A short questionnaire was administered to all subjects with questions on demographic information and environmental risk factors such as life-long smoking habits and alcohol consumption. The demographic data of both groups are presented in Table 1. Tobacco smoke exposure was measured in pack-years [1 pack-year = 1 pack (20 cigarettes)/day for 1 years]. This study was approved by the institutional review board at our institute and informed consent was obtained from all subjects.

Genotyping analysis

Genomic DNA was isolated from oral tissue samples or buccal cells by proteinase K digestion and phenol-chloroform extraction as previously described.29 The CYP1A1 MspI polymorphism was identified by PCR-restriction fragment length polymorphism (PCR-RFLP),30 testing for substitution of CCGG for CTGG in the MspI site at base 264 from the additional polyadenylation signal in the 3'-flanking region. Using two primers (5'-TAG GAGTCTTGTCTCATGCCT-3' and 5'-CAGTGAA GAGGTGTAGCCGCT-3'), PCR-amplification was performed using 30 cycles of 1 min at 95℃ for denaturation, 1 min at 65℃ for primer annealing and 1min at 72℃ for primer extension. The PCR products were digested with MspI and subjected to electrophoresis on a 2.0% agarose gel. The CYP1A1 (m1/m1) genotype (wild type) was characterized by a 340 bp fragment, polymorphic homozygous CYP1A1 (m2/m2) genotype by 140 and 200bp fragments, and heterozygous CYP1A1 (m1/m2) genotype by 140, 200 and 340bp fragments, respectively.
The GSTM1 genotypes were also determined by PCR analysis.30 Two primers (5'-GAACTCCCTGA AAAGCTAAAGC-3' and 5'-GTTGGGCTCAAAT ATACGGTGG-3') were used for 30 cycles of the amplification with 1 min at 94℃ for denaturation, 1min at 59℃ for primer annealing, 1min at 72℃ for extension. The PCR products were electrophoresed on a 2.0% agarose gel and the 215bp fragment in the GSTM1-positive genome was identified by ethidium bromide staining. A 268bp fragment of the β-goblin gene was co-amplified as an internal control. The primers for β-goblin were 5'-CAACTTCATCCACGTTCACC-3' and 5'-GAA GAGCCAAGGACAGGTAC-3'. The prevalence of the homozygous or heterozygous genotype of the complete GSTM1 gene [GSTM1 (+)], or the homozygous deficient gene [GSTM1 (-)] was compared between OSCC patients and healthy controls.

Statistical analysis

The risk of oral cancer in relation to polymorphic prevalence was estimated using conditional logistic regression to calculate the odds ratios (ORs) and 95% confidence intervals (CIs). The chi-squared test for trends was used in combined genotype analysis, and was implemented as appropriate for the analysis of categorical variables, genotypes and case status. The statistical computer software SPSS (ver. 11.5) was used to perform all statistical analyses (SPSS, 2003).31

RESULTS

A total of 72 cases and 221 controls were entered into this study (Table 1). The distribution of genotypes of CYP1A1 and GSTM1 among the patients with OSCC and healthy controls is shown in Table 2. The genotype distribution for CYP1A1 MspI polymorphisms among the controls (p = 0.10) followed the expected Hardy-Weinberg distribution. Due to the design of our genotyping analysis, we could not assess the allelic frequency of the GSTM1 allele.
Patients with OSCC were more likely to have homozygous CYP1A1 (m2/m2) genotypes when compared to controls (OR = 3.8, 95% CI = 1.9-7.7; Table 2). This data corresponded with a significantly higher prevalence of the CYP1A1 m2 allele (0.51) when compared to controls (0.40, p = 0.023). Conversely, a significant association was not observed between the GSTM1 (-) genotype and OSCC (OR = 0.7; 95% CI = 0.4-1.3; Table 2).
To evaluate gene-smoking interactions, the prevalence of CYP1A1 and GSTM1 genotypes were stratified by smoking history. Oral cancer was significantly increased in subjects with the homozygous CYP1A1 (m2/m2) genotype regardless of smoking history (smokers; OR = 4.4; 95% CI=1.2-16.3; non-smokers OR = 4.9; 95% CI = 1.9-12.5), whereas it was significantly decreased in smokers with the GSTM1 null genotype (OR = 0.3; 95% CI = 0.1-0.8) and a similar association was not observed among non-smokers (OR = 1.6; 95% CI = 0.7-3.6; Table 2).
To analyze the association between oral cancer and combined genotypes, the genotype presumed most protective, GSTM1 (+)/CYP1A1 [(m1/m1)+(m1/m2)], was used as the reference group. Increased risk for oral cancer was observed in subjects with the GSTM1 (+)/CYP1A1 (m2/m2) genotype (OR = 2.0, 95% CI = 0.8-5.2), as well as the genotype presumed most dangerous, GSTM1 (-)/ CYP1A1 (m2/m2) (OR = 4.9, 95% CI = 1.5-15.5) (Table 3). A significant trend towards increased risk was observed in the potentially less protective genotype GSTM1/CYP1A1 (p < 0.009, (Χ2 trend test).

DISCUSSION

Variations in the importance of the CYP1A1 and GSTM1 polymorphisms on the increased risk for smoking-related cancers have been demonstrated for different ethnic groups.8,21,27,32,33 Recently, the association between genetic polymorphisms in CYP1A1 and GSTM1 genes and oral cancer risk were studied in several populations.9-11,34-38 In a Japanese population, individuals with the CYP1A1 (m2/m2) and GSTM1 null genotype exhibited a remarkably high risk for oral cancer at a low dose level of cigarette smoking, even though the GSTM1 null genotype is only weakly correlated with oral cancer.9-11 In contrast, only GSTM1 and GSTT null genotypes resulting in the deficiency of these gene products was associated with oral cancer in a German population. Interestingly, the CYP1A1 (m2/m2) genotype is not seen in patients with oral cancer.39 In an Indian study, increases in the risk of oral leukoplakia and cancer were observed in individuals with the GSTM1 null genotype,35,38 but the combined homozygous and heterozygous mutated genotypes of CYP1A1 did not show any significant differences between patients with oral leukoplakia and controls among tobacco smokers.40 It has also been reported that the GSTM1 null polymorphism plays a significant role in individual risk for oral cancer in the African Americans25 and Brazilians,37 but not in Caucasians.8,26,33 The discrepancy between these results may be due to several factors, including differences between the study populations in tumor site, ethnicity and sample size.
In this study, we investigated the role of singular and combined genotypes of CYP1A1 and GSTM1 in the risk for oral cancer in a Korean population. The results from the present study demonstrate that harboring a homozygous CYP1A1 (m2/m2) genotype adds a significant risk increase for oral cancer in both smokers and non-smokers. The lack of an association between the GSTM1 null genotype and susceptibility to oral cancer in our study is similar to the results reported in previous studies.8,9,23 As the significance of the protective effect of the GSTM1 null genotype for smokers is presently unclear, these results need to be confirmed with further studies.
The magnitude of the risk increase from the CYP1A1 (m2/m2) genotype for oral cancer was more evident in subjects who were GSTM1 null (OR = 4.9, 95% CI = 1.5-15.5) than subjects with the GSTM1 (+) genotype (OR = 2.0, 95% CI = 0.8-5.2). This data suggests that CYP1A1 and GSTM1 gene: gene interactions play a critical role in susceptibility to oral cancer. This interaction can be explained by the risk association for genotypes exhibiting small increases in CYP1A1 activity only being discernable under circumstances where exposure to BaP-7,8-epoxide is greatest. That the CYP1A1 genotype plays an important role in oral cancer risk exclusively in GSTM1 null subjects is consistent with this hypothesis since increased levels of BaP-7,8-epoxide would be present due to decreased rates of detoxification by the GSTM1 enzyme. As discussed above, no association between the GSTM1 null polymorphism and oral cancer was observed in the present study. Taken together, these data suggest that the GSTM1 null genotype is not associated with oral cancer risk regardless of CYP1A1 genotype {CYP1A1 (m2/m2): OR = 2.4, 95% CI = 0.6-9.1, CYP1A1 [(m1/m1)+(m1/m2)]: OR = 0.7, 95% CI = 0.4-1.4}. Therefore, the risk associated with the GSTM1 null polymorphism may only be discernable when the combined net effect of multiple genotypes results in significant increases in BaP-7,8-epoxide levels.
Several variables could contribute to these conlicting results, with the greatest concern being a common problem with molecular epidemiological studies, an inadequate sample size to allow sufficient measurement of attributable risk associated with any given genotype. In summary, this work demonstrated that individuals with the CYP1A1 (m2/m2) GSTM1 (-) genotype are susceptible for OSCC and the presence of the CYP1A1 (m2/m2) genotype is closely associated with increased risk of OSCC regardless of smoking behavior in Korean populations.

Figures and Tables

Table 1
Age, Gender and Smoking History of Controls and Oral Cancer Patients
ymj-48-233-i001

*Standard deviation.

†Smoking information from nine cases is not available.

py, the number of pack/day x years of smoking.

Table 2
Distribution of CYP1A1 and GSTM1 Genotypes and Risk for Oral Cancer Stratified by Smoking Behavior
ymj-48-233-i002

*Numbers in parenthesis denote percentages.

†(+) = homozygous (+/+) and heterozygous (+/0) genotypes.

‡(-) = null genotype for GSTM1.

Table 3
Distribution of Combined GSTM1 and CYP1A1 Genotypes Among Study Subjects
ymj-48-233-i003

*(+) = homozygous (+/+) and heterozygous (+/0) genotypes.

†Numbers in parentheses denote percentages.

‡Chi square trend test, p < 0.009.

§(-) = null genotype for GSTM1.

Notes

This study was supported by a grant from the Research Fund of Yonsei University College of Dentistry to Kwang-Kyun Park for 2005.

References

1. Nebert DW. Role of genetics and drug metabolism in human cancer risk. Mutat Res. 1991. 247:267–281.
2. Nakajima T, Elovaara E, Anttila S, Hirvonen A, Camus AM, Hayes JD, et al. Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. Carcinogenesis. 1995. 16:707–711.
3. Lin P, Wang SL, Wang HJ, Chen KW, Lee HS, Tsai KJ, et al. Association of CYP1A1 and microsomal epoxide hydrolase polymorphisms with lung squamous cell carcinoma. Br J Cancer. 2000. 82:852–857.
4. McWilliams JE, Sanderson BJ, Harris EL, Richert-Boe KE, Henner WD. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 1995. 4:589–594.
5. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1997. 9:733–743.
6. Sugimura H, Suzuki I, Hamada GS, Iwase T, Takahashi T, Nagura K, et al. Cytochrome P-450 lA1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil. Cancer Epidemiol Biomarkers Prev. 1994. 3:145–148.
7. Shields PG, Caporaso NE, Falk RT, Sugimura H, Trivers GE, Trump BF, et al. Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev. 1993. 2:481–485.
8. Park JY, Muscat JE, Ren Q, Schantz SP, Harwick RD, Stern JC, et al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomarkers Prev. 1997. 6:791–797.
9. Tanimoto K, Hayashi S, Yoshiga K, Ichikawa T. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol. 1999. 35:191–196.
10. Sato M, Sato T, Izumo T, Amagasa T. Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis. 1999. 20:1927–1931.
11. Katoh T, Kaneko S, Kohshi K, Munaka M, Kitagawa K, Kunugita N, et al. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer. 1999. 83:606–609.
12. Phillips DH. Fifty years of benzo(a)pyrene. Nature. 1983. 303:468–472.
13. Rojas M, Cascorbi I, Alexandrov K, Kriek E, Auburtin G, Mayer L, et al. Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis. 2000. 21:35–41.
14. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett. 1990. 263:131–133.
15. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A, et al. Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics. 1991. 1:20–25.
16. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev. 1992. 1:485–489.
17. Xu X, Kelsey KT, Wiencke JK, Wain JC, Christiani DC. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1996. 5:687–692.
18. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res. 1992. 83:866–870.
19. Kao SY, Wu CH, Lin SC, Yap SK, Chang CS, Wong YK, et al. Genetic polymorphism of cytochrome P4501A1 and susceptibility to oral squamous cell carcinoma and oral precancer lesions associated with smoking/betel use. J Oral Pathol Med. 2002. 31:505–511.
20. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995. 30:445–600.
21. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993. 85:1159–1164.
22. Jourenkova N, Reinikainen M, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev. 1998. 7:19–23.
23. Park LY, Muscat JE, Kaur T, Schantz SP, Stern JC, Richie JP Jr, et al. Comparison of GSTM polymorphisms and risk for oral cancer between African-Americans and Caucasians. Pharmacogenetics. 2000. 10:123–131.
24. Kihara M, Kihara M, Kubota A, Furukawa M, Kimura H. GSTM1 gene polymorphism as a possible marker for susceptibility to head and neck cancers among Japanese smokers. Cancer Lett. 1997. 112:257–262.
25. Buch SC, Notani PN, Bhisey RA. Polymorphism at GSTM1, GSTM3 and GSTM3 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis. 2002. 23:803–807.
26. Hung HC, Chuang J, Chien YC, Chern HD, Chiang CP, Kuo YS, et al. Genetic polymorphisms of CYP2E1, GSTM1, and GSTM3; environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev. 1997. 6:901–905.
27. Deakin M, Elder J, Hendrickse C, Peckham D, Baldwin D, Pantin C, et al. Glutathione S-transferase GSTM3 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis. 1996. 17:881–884.
28. Lum A, Le Marchand L. A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomarkers Prev. 1998. 7:719–724.
29. Ausubel FM, Brent R, Kingston R, Moore DD, Seidman JG, Smith JA. Current Protocols in Molecular Biology. 1988. Vol. 1. New York: John Wiley and Sons.
30. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem(Tokyo). 1991. 110:407–411.
31. SPSS. SPSS base 11.5 for windows, User's guide. 2003. Chicago: SPSS Inc..
32. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993. 53:2994–2999.
33. Kihara M, Kihara M, Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis. 1994. 15:415–418.
34. Sato M, Sato T, Izumo T, Amagasa T. Genetically high susceptibility to oral squamous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes. Oral Oncol. 2000. 36:267–271.
35. Sreelekha TT, Ramadas K, Pandey M, Thomas G, Nalinakumari KR, Pillai MR. Genetic polymorphism of CYP1A1, GSTM1 and GSTM3 genes in Indian oral cancer. Oral Oncol. 2001. 37:593–598.
36. Hahn M, Hagedorn G, Kuhlisch E, Schackert HK, Eckelt U. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol. 2002. 38:486–490.
37. Drummond SN, De Marco L, Noronha JC, Gomez RS. GSTM1 polymorphism and oral squamous cell carcinoma. Oral Oncol. 2004. 40:52–55.
38. Sikdar N, Paul RR, Roy B. Glutathione S-transferase M3 (A/A) genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers. Int J Cancer. 2004. 109:95–101.
39. Gronau S, Koenig-Greger D, Jerg M, Riechelmann H. GSTM1 enzyme concentration and enzyme activity in correlation to the genotype of detoxication enzymes in squamous cell carcinoma of the oral cavity. Oral Dis. 2003. 9:62–67.
40. Sikdar N, Mahmud SA, Paul RR, Roy B. Polymorphism in CYP1A1 and CYP2E1 genes and susceptibility to leukoplakia in Indian tobacco users. Cancer Lett. 2003. 195:33–42.
TOOLS
Similar articles